Soissons

Researchers are studying patients with rotator cuff injuries who are undergoing arthroscopic rotator cuff repair surgery. This study collects real-world data on the outcomes of using the REGENETEN Bioinductive Implant System, a medical device designed to manage and protect rotator cuff tendon injuries where there has been no significant loss of tendon tissue. The registry involves multiple centers across the United Kingdom, Europe, and Australia and plans to enroll up to 400 patients. Participants will receive arthroscopic rotator cuff repair surgery augmented with the REGENETEN Bioinductive Implant as part of their standard medical care. The implant is intended to support tendon healing in either partial or full thickness tendon tears. This is a prospective, single-arm study without a comparison group, focusing on collecting data after surgery. Patients will be followed and evaluated at multiple time points up to two years after surgery. Assessments include quality of life, arm and shoulder function, shoulder pain levels, and overall shoulder evaluation using several validated scoring systems. Data will be collected at baseline before surgery and at 2 weeks, 6 weeks, 3 months, 6 months, 12 months, and 24 months post-surgery to monitor recovery and outcomes over time.

Researchers are investigating factors that predict resistance to pembrolizumab, an immune therapy, in patients with metastatic colorectal cancer characterized by microsatellite instability (MSI) or mismatch repair deficiency (dMMR). This research follows findings from the Keynote 177 trial, which showed pembrolizumab's superiority over chemotherapy but also noted that 20-30% of patients experienced primary resistance. The goal is to identify biomarkers that can help determine who will benefit most from immunotherapy and who may need alternative treatments. This study involves a national French cohort including both retrospective and prospective patients treated with pembrolizumab as first-line therapy for MSI/dMMR metastatic colorectal cancer. Patients treated since February 2021 under compassionate use and those starting treatment from February 2024 onward will be included. Recruitment will take place across over 150 French public and private centers, with an anticipated total enrollment of 600 patients over two years. Participants will be followed for three years to monitor their response to pembrolizumab and identify factors linked to resistance. Researchers will collect clinical data and tumor characteristics to analyze predictive biomarkers. The primary outcome is to find factors that predict resistance over a two-year period. The study emphasizes long-term follow-up to better understand treatment outcomes and improve patient selection for immunotherapy.